Lieping Chen
Yale University · 653 works · 95,172 citations · h-index 131
Top works
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
- Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
- Inhibitory B7-family molecules in the tumour microenvironment
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
- Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
- Immunostimulatory monoclonal antibodies for cancer therapy
- Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
- Programmed death ligand-1 expression in non-small cell lung cancer
- B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- Molecular mechanisms of T cell co-stimulation and co-inhibition
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody